EGFR and non-Hodgkin lymphoma: Sex-specific differences are observed in the efficacy of certain treatments, including epidermal growth factor receptor (EGFR) inhibitors in NSCLC and rituximab (a CD20 monoantibody) in NHL, which go beyond the general disparities in survival between sexes in these two cancers.